Cargando…

A 2 × 2 factorial design for the combination therapy of minocycline and remote ischemic perconditioning: efficacy in a preclinical trial in murine thromboembolic stroke model

BACKGROUND: After the failure of so many drugs and therapies for acute ischemic stroke, innovative approaches are needed to develop new treatments. One promising strategy is to test combinations of agents in the pre-hospital setting prior to the administration of intravenous tissue plasminogen activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoda, Md Nasrul, Fagan, Susan C, Khan, Mohammad B, Vaibhav, Kumar, Chaudhary, Aizaz, Wang, Phillip, Dhandapani, Krishnan M, Waller, Jennifer L, Hess, David C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204390/
https://www.ncbi.nlm.nih.gov/pubmed/25337387
http://dx.doi.org/10.1186/2040-7378-6-10
_version_ 1782340558830698496
author Hoda, Md Nasrul
Fagan, Susan C
Khan, Mohammad B
Vaibhav, Kumar
Chaudhary, Aizaz
Wang, Phillip
Dhandapani, Krishnan M
Waller, Jennifer L
Hess, David C
author_facet Hoda, Md Nasrul
Fagan, Susan C
Khan, Mohammad B
Vaibhav, Kumar
Chaudhary, Aizaz
Wang, Phillip
Dhandapani, Krishnan M
Waller, Jennifer L
Hess, David C
author_sort Hoda, Md Nasrul
collection PubMed
description BACKGROUND: After the failure of so many drugs and therapies for acute ischemic stroke, innovative approaches are needed to develop new treatments. One promising strategy is to test combinations of agents in the pre-hospital setting prior to the administration of intravenous tissue plasminogen activator (IV-tPA) and/ or the use of mechanical reperfusion devices in the hospital. METHODS: We performed a 2 × 2 factorial design preclinical trial where we tested minocycline (MINO), remote ischemic perconditioning (RIPerC) and their combination treatment in a thromboembolic clot model of stroke in mice, without IV-tPA or later treated with IV-tPA at 4 hours post-stroke. Cerebral blood flow (CBF) was measured by laser speckle contrast imaging (LSCI), behavioral outcomes as neurological deficit score (NDS) and adhesive tape removal test, and infarct size measurement were performed at 48 hours post-stroke. Mice within the experimental sets were randomized for the different treatments, and all outcome measures were blinded. RESULTS: RIPerC significantly improved CBF as measured by LSCI in both with and without tPA treated mice (P < 0.001). MINO and RIPerC treatment were effective alone at reducing infarct size (p < 0.0001) and improving short-term functional outcomes (p < 0.001) in the tPA and non-tPA treated animals. The combination treatment of MINO and RIPerC significantly reduced the infarct size greater than either intervention alone (p < 0.05). There were trends in favor of improving functional outcomes after combination treatment of MINO and RIPerC; however combination treatment group was not significantly different than the individual treatments of MINO and RIPerC. There was no “statistical” interaction between minocycline and RIPerC treatments indicating that the effects of RIPerC and MINO were additive and not synergistic on the outcome measures. CONCLUSION: In the future, combining these two safe and low cost interventions in the ambulance has the potential to “freeze” the penumbra and improve outcomes in stroke patients. This pre-clinical 2 × 2 design can be easily translated into a pre-hospital clinical trial.
format Online
Article
Text
id pubmed-4204390
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42043902014-10-22 A 2 × 2 factorial design for the combination therapy of minocycline and remote ischemic perconditioning: efficacy in a preclinical trial in murine thromboembolic stroke model Hoda, Md Nasrul Fagan, Susan C Khan, Mohammad B Vaibhav, Kumar Chaudhary, Aizaz Wang, Phillip Dhandapani, Krishnan M Waller, Jennifer L Hess, David C Exp Transl Stroke Med Research BACKGROUND: After the failure of so many drugs and therapies for acute ischemic stroke, innovative approaches are needed to develop new treatments. One promising strategy is to test combinations of agents in the pre-hospital setting prior to the administration of intravenous tissue plasminogen activator (IV-tPA) and/ or the use of mechanical reperfusion devices in the hospital. METHODS: We performed a 2 × 2 factorial design preclinical trial where we tested minocycline (MINO), remote ischemic perconditioning (RIPerC) and their combination treatment in a thromboembolic clot model of stroke in mice, without IV-tPA or later treated with IV-tPA at 4 hours post-stroke. Cerebral blood flow (CBF) was measured by laser speckle contrast imaging (LSCI), behavioral outcomes as neurological deficit score (NDS) and adhesive tape removal test, and infarct size measurement were performed at 48 hours post-stroke. Mice within the experimental sets were randomized for the different treatments, and all outcome measures were blinded. RESULTS: RIPerC significantly improved CBF as measured by LSCI in both with and without tPA treated mice (P < 0.001). MINO and RIPerC treatment were effective alone at reducing infarct size (p < 0.0001) and improving short-term functional outcomes (p < 0.001) in the tPA and non-tPA treated animals. The combination treatment of MINO and RIPerC significantly reduced the infarct size greater than either intervention alone (p < 0.05). There were trends in favor of improving functional outcomes after combination treatment of MINO and RIPerC; however combination treatment group was not significantly different than the individual treatments of MINO and RIPerC. There was no “statistical” interaction between minocycline and RIPerC treatments indicating that the effects of RIPerC and MINO were additive and not synergistic on the outcome measures. CONCLUSION: In the future, combining these two safe and low cost interventions in the ambulance has the potential to “freeze” the penumbra and improve outcomes in stroke patients. This pre-clinical 2 × 2 design can be easily translated into a pre-hospital clinical trial. BioMed Central 2014-10-09 /pmc/articles/PMC4204390/ /pubmed/25337387 http://dx.doi.org/10.1186/2040-7378-6-10 Text en Copyright © 2014 Hoda et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Hoda, Md Nasrul
Fagan, Susan C
Khan, Mohammad B
Vaibhav, Kumar
Chaudhary, Aizaz
Wang, Phillip
Dhandapani, Krishnan M
Waller, Jennifer L
Hess, David C
A 2 × 2 factorial design for the combination therapy of minocycline and remote ischemic perconditioning: efficacy in a preclinical trial in murine thromboembolic stroke model
title A 2 × 2 factorial design for the combination therapy of minocycline and remote ischemic perconditioning: efficacy in a preclinical trial in murine thromboembolic stroke model
title_full A 2 × 2 factorial design for the combination therapy of minocycline and remote ischemic perconditioning: efficacy in a preclinical trial in murine thromboembolic stroke model
title_fullStr A 2 × 2 factorial design for the combination therapy of minocycline and remote ischemic perconditioning: efficacy in a preclinical trial in murine thromboembolic stroke model
title_full_unstemmed A 2 × 2 factorial design for the combination therapy of minocycline and remote ischemic perconditioning: efficacy in a preclinical trial in murine thromboembolic stroke model
title_short A 2 × 2 factorial design for the combination therapy of minocycline and remote ischemic perconditioning: efficacy in a preclinical trial in murine thromboembolic stroke model
title_sort 2 × 2 factorial design for the combination therapy of minocycline and remote ischemic perconditioning: efficacy in a preclinical trial in murine thromboembolic stroke model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204390/
https://www.ncbi.nlm.nih.gov/pubmed/25337387
http://dx.doi.org/10.1186/2040-7378-6-10
work_keys_str_mv AT hodamdnasrul a22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT fagansusanc a22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT khanmohammadb a22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT vaibhavkumar a22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT chaudharyaizaz a22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT wangphillip a22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT dhandapanikrishnanm a22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT wallerjenniferl a22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT hessdavidc a22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT hodamdnasrul 22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT fagansusanc 22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT khanmohammadb 22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT vaibhavkumar 22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT chaudharyaizaz 22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT wangphillip 22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT dhandapanikrishnanm 22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT wallerjenniferl 22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel
AT hessdavidc 22factorialdesignforthecombinationtherapyofminocyclineandremoteischemicperconditioningefficacyinapreclinicaltrialinmurinethromboembolicstrokemodel